Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
0(0%)
Results Posted
17%(1 trials)

Phase Distribution

Ph phase_4
1
17%
Ph not_applicable
1
17%
Ph phase_2
1
17%
Ph phase_1
1
17%
Ph phase_3
1
17%

Phase Distribution

1

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
1(20.0%)
Phase 4Post-market surveillance
1(20.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(6)

Detailed Status

Completed6

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (20.0%)
Phase 21 (20.0%)
Phase 31 (20.0%)
Phase 41 (20.0%)
N/A1 (20.0%)

Trials by Status

completed6100%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_1

Phenserine on the Alzheimer's Treatment Horizon, Study 1

NCT06774261
completedphase_2

Investigating the Cholinergic Contribution to Gait Dysfunction in Parkinson's Disease

NCT06903910
completedphase_4

Corticolimbic Degeneration and Treatment of Dementia

NCT00768261
completedphase_3

A Study of the Efficacy and Safety of Aricept in Patients With Severe Alzheimer's Disease Who Are Living in Skilled Nursing Homes

NCT00630851
completed

Effect of Aricept on Biomarkers (Acetylcholine, sAPP Alpha) In Cerebrospinal Fluid

NCT00987220
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06774261Phase 1

Phenserine on the Alzheimer's Treatment Horizon, Study 1

Completed
NCT06903910Phase 2

Investigating the Cholinergic Contribution to Gait Dysfunction in Parkinson's Disease

Completed
NCT00768261Phase 4

Corticolimbic Degeneration and Treatment of Dementia

Completed
NCT00630851Phase 3

A Study of the Efficacy and Safety of Aricept in Patients With Severe Alzheimer's Disease Who Are Living in Skilled Nursing Homes

Completed
NCT00987220

Effect of Aricept on Biomarkers (Acetylcholine, sAPP Alpha) In Cerebrospinal Fluid

Completed
NCT00467766Not Applicable

Combining a Caregiver Intervention With Aricept Treatment for Mild to Moderate Alzheimer's Disease

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6